Group 1 - The core point of the article is that Liu Pharmaceutical Group announced that it does not provide guarantees for its controlling shareholders, actual controllers, or their related parties [2] - The company confirmed that there are no overdue guarantees [2]

一、会议基本情况 （四）公司参会人员及职务： 副总裁兼财务总监曾祥兴先生、董事会秘书徐扬先生 广西柳药集团股份有限公司 投资者交流会议记录 证券代码：603368 证券简称：柳药集团 （五）调研机构名称（排名不分先后）： 工银瑞信基金、中银基金、红土创新基金、光大保德信基金、生命保险资产、 上海灏象资产、上海同犇投资、华泰证券、信达证券、中邮证券、平安证券、国盛 证券、兴业证券、浙商证券、Capital group 等机构。 二、会议交流主要内容 （一）介绍公司 2025 年半年度经营情况 2025年上半年，公司坚持"稳中求进，协同创新"发展策略，一方面坚持"有 所为有所不为"标准，强化风险防控能力，稳住基本盘的同时抢占优质市场、拓展 新的业务领域；另一方面发挥"药械协同、批零协同、工商协同"优势，强化渠道 资源共享，产业链协作，推动优质创新药械产品的引进和终端药械市场份额提升， 加快自产工业产品的市场拓展，并应用新技术赋能企业精细化管理、智慧供应链体 系建设、专业健康服务升级，积极打造"AI+医疗"全场景应用，以数字化、精细化、 专业化、生态化、协同化驱动企业降本增效、传统业态转型和工业做大做强，实现 企业 ...

二〇二五年九月十五日 广西柳药集团股份有限公司 2025 年第二次临时股东会 会 议 文 件 | 序号 | 议案名称 | | --- | --- | | 1 | 《关于变更注册资本、取消监事会及修订<公司章程>的议案》 | | 2.00 | 《关于修订、制定公司部分治理制度的议案》 | | 2.01 | 《股东会议事规则》 | | 2.02 | 《董事会议事规则》 | | 2.03 | 《独立董事工作制度》 | | 2.04 | 《募集资金管理制度》 | | 3 | 《关于购买董事、高级管理人员责任险的议案》 | | 4 | 年股票期权激励计划（草案） 《关于<广西柳药集团股份有限公司 2025 | | | 及其摘要>的议案》 | | 5 | 《关于<广西柳药集团股份有限公司 年股票期权激励计划实施考核 2025 | | | 管理办法>的议案》 | | 6 | 《关于核实<广西柳药集团股份有限公司 年股票期权激励计划激励 2025 | | | 对象名单>的议案》 | 3 | | | 2025 年第二次临时股东会会议议程 广西柳药集团股份有限公司 2025 年第二次临时股东会会议议程 一、会议基本情况 二、会议 ...

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-074 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于为下属控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | | 广西南宁柳药药业有限公司（简称"南宁柳药"） | | --- | --- | --- | --- | --- | | | 本次担保金额 | 1,298.11 | 万元 | | | 担保 对象一 | 实际为其提供的担保余额 | 139,094.77 | | 万元（含本次） | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | 担保 | 被担保人名称 | | | 广西仙茱制药有限公司（简称"仙茱制药"） | | | 本次担保金额 | 2, ...

Group 1 - The core point of the article is that Liu Pharmaceutical Group announced a share buyback, having repurchased 5.0745 million shares, which represents 1.28% of the company's total share capital as of August 31, 2025 [2]

Group 1 - The company, Liu Pharmaceutical Group (603368.SH), announced a share buyback program, with a total of 5.0745 million shares repurchased as of August 31, 2025 [1] - The repurchased shares account for 1.28% of the company's total share capital [1] - The highest price for the repurchased shares was 18.60 yuan per share, while the lowest price was 18.08 yuan per share, with a total expenditure of 93.5503 million yuan (excluding transaction fees) [1]

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-073 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于以集中竞价交易方式股份回购的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/7/26 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 7 月 7 月 | 25 | 日~2026 | 年 | 24 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 507.45万股 | | | | | | 累计已回购股数占总股本比例 | ...

Financial Performance - The company reported a net profit of 429 million yuan for the first half of 2025, a year-on-year decrease of 7.52% [1] - Total operating revenue for the same period was 10.301 billion yuan, down 3.21% year-on-year [1] - The gross profit margin was 11.07%, a decrease of 6.28% compared to the previous year [1] - The net profit margin was 4.26%, down 7.72% year-on-year [1] - Earnings per share decreased by 12.9% to 1.08 yuan [1] Cash Flow and Debt - The company has a healthy cash position, with cash assets being robust [2] - The estimated dividend yield is 4.27% [3] - The cash flow situation is a point of concern, with cash assets to current liabilities ratio at 39.9% and the average operating cash flow to current liabilities ratio at 7.8% over the past three years [5] - The interest-bearing debt ratio has reached 22.27% [5] Business Model and Market Position - The company's performance is primarily driven by marketing efforts, necessitating a deeper analysis of the underlying drivers [4] - The company’s return on invested capital (ROIC) was 8.85% last year, indicating average capital returns [1] - Analysts expect the company's performance for 2025 to be around 849 million yuan, with an average earnings per share forecast of 2.14 yuan [6] Shareholder Information - The largest fund holding the company’s shares is the Hongtu Innovation Stable Mixed A fund, with a holding of 112,200 shares [7] - The fund's current scale is 0.75 billion yuan, with a recent net value of 1.6008, reflecting a 4.18% increase over the past year [7]

Core Viewpoint - The board of directors of Guangxi Liuyuan Pharmaceutical Group Co., Ltd. held its 28th meeting, approving several key proposals including the half-year report and various governance changes aimed at enhancing operational efficiency and corporate governance [1][2][3]. Meeting Details - The board meeting was held on August 28, 2025, with all 7 directors present, ensuring compliance with legal and procedural requirements [1]. Financial Reports - The board approved the 2025 half-year report and its summary, with unanimous support from all directors [2]. - A special report on the use of raised funds was also approved, reflecting accurate management of funds during the reporting period [2]. Governance Changes - The board approved a proposal to change the registered capital and abolish the supervisory board, transferring some supervisory functions to the audit committee [3][4]. - A comprehensive revision of the company's articles of association was proposed to align with governance and regulatory requirements [3][4]. Risk Management - The board proposed purchasing liability insurance for directors and senior management to mitigate operational risks, with the proposal to be submitted to the shareholders' meeting due to conflicts of interest [7]. Incentive Plans - The board approved a draft for the 2025 stock option incentive plan aimed at attracting and retaining talent, which will also be submitted for shareholder approval [10][11]. - A management method for the stock option incentive plan was also approved, ensuring alignment with corporate goals [11][12]. Employee Stock Ownership Plan - The board approved a draft for the 2025 employee stock ownership plan to enhance employee engagement and align interests with shareholders, pending shareholder approval [15][16]. - A management method for the employee stock ownership plan was also established, ensuring compliance with relevant regulations [16][17]. Upcoming Meetings - The board scheduled the second extraordinary shareholders' meeting for September 15, 2025, to review the approved proposals [18].

Core Viewpoint - The company has conducted a necessary review of its 2025 Employee Stock Ownership Plan (ESOP) and has confirmed that the plan complies with relevant laws and regulations, aiming to enhance corporate governance and employee engagement [1][2]. Group 1: Compliance and Legal Framework - The review by the company's Compensation and Assessment Committee indicates that the ESOP adheres to the Company Law, Securities Law, and other regulatory guidelines [1]. - The plan's content is in line with the prohibitions outlined in the self-regulatory guidelines, ensuring that there are no circumstances that would prevent the implementation of the ESOP [1][2]. Group 2: Employee Participation and Benefits - The ESOP does not involve any forced participation or financial assistance from the company to the plan participants, ensuring voluntary engagement [2]. - The plan is designed to improve corporate governance, attract and retain talented management and key personnel, and enhance employee cohesion and company competitiveness [2].